A real-world study on the efficacy and safety of ondansetron oral dissolving film in preventing chemotherapy, radiotherapy, and postoperative nausea and vomiting

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400089063

Enrollment

Unknown

Registered

2024-08-30

Start date

2024-01-09

Completion date

Unknown

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vomit

Interventions

Prospective group:None

Retrospective group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age and gender are not limited; (2) Patients receiving chemotherapy; radiotherapy; surgery; (3) Use ondansetron orally dissolving film for at least 3 days;

Exclusion criteria

Exclusion criteria: (1) The researcher determines any situation that is unstable or may endanger the subject’s safety and compliance with the study; (2) Pregnant or lactating women; (3) Are allergic to study drugs and excipients or have had severe adverse reactions before;

Design outcomes

Primary

Measure	Time frame
Incidence and severity of nausea and vomiting in the acute phase (during 24 hours after chemotherapy/radiotherapy/surgery);	—

Secondary

Measure	Time frame
Incidence and severity of nausea and vomiting in patients in the delayed period (48-72 hours after chemotherapy/radiotherapy/surgery);PRO;Safety;	—

Countries

China

Contacts

Public ContactZhu Liangjun

Jiangsu Cancer Hospital

Zhulj98@foxmail.com+86 135 0519 9123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026